Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating macitentan 75 mg for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension was terminated, and its results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• OPSUMIT (macitentan)

Snippet

Sponsor: Actelion | Conditions: Chronic Thromboembolic Pulmonary Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2025-04-22